Biologic drugs have transformed the treatment of psoriasis, atopic dermatitis, inflammatory bowel disease, and a host of other immune-mediated conditions, offering targeted relief where older systemic ...

Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...

The European Commission has approved ICOTYDE® for eligible psoriasis patients aged 12 and over. The once-daily oral peptide ...

Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTAL study demonstrating the positive impact of ICOTYDE® (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is ...

Icotrokinra (Icotyde) produced skin clearance through 2 years in patients with plaque psoriasis affecting the scalp, genitals, hands, and feet, with 70% achieving clear or almost ...

Johnson & Johnson , a pharmaceutical company, released on Friday new results from the Phase 3 ICONIC-TOTAL study of ICOTYDE on high-impact plaque psoriasis (PsO) sites. The data w ...

Johnson & Johnson stock rebounds as ICOTYDE delivers strong two-year psoriasis results, showing sustained skin clearance and ...

Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the ...

US healthcare company Johnson & Johnson (NYSE: JNJ) on Friday announced the release of two-year Phase 3 results from ICONIC-TOTAL assessing ICOTYDE (icotrokinra) in adults and adolescents with ...

Takeda announces positive data from three phase 3 LATITUDE psoriasis studies of zasocitinib in adults with moderate-to-severe plaque psoriasis: Osaka, Japan Thursday, October 1, 2 ...

A trichologist explains how oil, dryness, weather, and stress can affect your scalp—and when your routine may need an update.

AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and ...